NewsWorld
PredictionsDigestsScorecardTimelinesArticles
NewsWorld
HomePredictionsDigestsScorecardTimelinesArticlesWorldTechnologyPoliticsBusiness
AI-powered predictive news aggregation© 2026 NewsWorld. All rights reserved.
For live open‑source updates on the Middle East conflict, visit the IranXIsrael War Room.

A real‑time OSINT dashboard curated for the current Middle East war.

Open War Room

Trending
IranNuclearMilitaryStrikesCrisisChinaConflictIsraeliIranianPricesMarchOperationsEuropeanTimelineMarketsSupremeDigestTrumpRegionalLeaderHormuzFacesGulfFacilities
IranNuclearMilitaryStrikesCrisisChinaConflictIsraeliIranianPricesMarchOperationsEuropeanTimelineMarketsSupremeDigestTrumpRegionalLeaderHormuzFacesGulfFacilities
All Articles
STAT+: CMS halts enrollment in Elevance’s Medicare Advantage plans, citing years of misconduct
STAT News
Published about 7 hours ago

STAT+: CMS halts enrollment in Elevance’s Medicare Advantage plans, citing years of misconduct

STAT News · Mar 2, 2026 · Collected from RSS

Summary

CMS said Elevance had "substantial and persistent noncompliance" with requirements to submit information about its customers.

Full Article

Insurer’s conduct ‘demonstrates a pattern of knowing noncompliance,’ CMS officials say Michael Conroy/AP By Bob HermanMarch 2, 2026 Business of Health Care Reporter Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09. Elevance Health will no longer be able to enroll people into its Medicare Advantage plans starting March 31, according to a new, harshly worded suspension notice from the Centers for Medicare and Medicaid Services. CMS is imposing the punishment after Elevance failed to submit required information to federal regulators over a seven-year period, the government said. The suspension will not affect the 1.9 million people who were already enrolled in an Elevance Medicare Advantage plan heading into this year. CMS rarely issues these kinds of sanctions — a serious measure that could financially crush Elevance if the company doesn’t fix things by the start of Medicare’s annual enrollment window in October. The government said that if Elevance takes certain steps to start addressing the issues this month, it won’t suspend enrollment. Elevance’s shares tumbled more than 8% Monday. STAT+ Exclusive Story Already have an account? Log in This article is exclusive to STAT+ subscribers Unlock this article — plus daily market-moving biopharma analysis — by subscribing to STAT+. Already have an account? Log in View All Plans To read the rest of this story subscribe to STAT+. Subscribe Business of Health Care Reporter Bob Herman covers health insurance, government programs, hospitals, physicians, and other providers — reporting on how money influences those businesses and shapes what we all pay for care. He is also the author of the Health Care Inc. newsletter. You can reach Bob on Signal at bobjherman.09.


Share this story

Read Original at STAT News

Related Articles

STAT Newsabout 7 hours ago
STAT+: Aetna’s ACA hospital prices, and a new Cigna deal

The health insurer paid higher prices for hospital care than some rivals in the ACA insurance market.

STAT Newsabout 10 hours ago
STAT+: A Merck cancer drug to watch

UniQure seeks approval, Novartis settles Henrietta Lacks lawsuit, and more biotech stories

STAT Newsabout 11 hours ago
A swine flu case to keep tabs on

The "godfather of vaccines," a case of swine flu, and other health news from Morning Rounds

STAT Newsabout 11 hours ago
STAT+: Pharmalittle: We’re reading about Trump’s MFN deals, 340B program controversies, and much more

The most-favored nation drug pricing deals the Trump administration reached with 16 drugmakers end after three years in some cases, according to SEC filings

STAT Newsabout 12 hours ago
STAT+: UniQure plans to seek approval for Huntington’s therapy still blocked by FDA

UniQure said plans to seek approval for its Huntington’s disease treatment with the FDA remain blocked.

STAT Newsabout 15 hours ago
Opinion: I analyzed 6 months of Reddit discussion about at-home ketamine therapy. The findings alarmed me

“Telehealth ketamine has crossed the line from innovation to abdication of care,” writes Michael Alvear.